Arecor Therapeutics PLC Ordinary Shares (AREC)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
60.00p
Buy
65.00p
-2.50p (-3.85%)
Prices updated at 12 Jun 2026, 17:13 BST
| Prices minimum 15 mins delay
Prices in GBX
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platfo ...
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Andrew John McGlashan Richards CBE
CEO
Ms. Sarah Jennifer Howell
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
33
Head office
Chesterford Research Park
Saffron Walden
United Kingdom
CB10 1XL
Key personnel
Owner name | Salary |
|---|---|
Dr. Andrew John McGlashan Richards CBE Non-Executive Director, Chairman | - |
Mr. Mohammad Sohail Fazeli Non-Executive Director | - |
Mr. Jeremy Lewis Morgan Non-Executive Director | - |
Mr. David Ellam Executive Director, Chief Financial Officer and Company Secretary | - |
Ms. Sarah Jennifer Howell Executive Director, Chief Executive Officer | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Unicorn Asset Management Ltd | 1,198,828 |
| Unicorn AIM VCT Series 3 ORD | 1,198,828 |
| Hargreave Hale Limited | 517,518 |
| Calculus Capital Limited | 425,287 |
| TM Oberon UK Special Situations Fund | 389,897 |
Director dealings
Date | Action |
|---|---|
| No data | |
Please note that past performance is not a reliable indicator of future returns.